GEHCMEDIUM SIGNALFINANCIAL10-K

GEHC shows strong financial performance with a 56% surge in cash reserves to $4.5B and 23% growth in stockholders' equity, while maintaining operational expansion through increased inventory and debt financing.

The substantial cash increase combined with growing equity suggests GEHC has significantly strengthened its financial position, likely through strong operational performance and potentially favorable financing activities. The company appears to be in an investment phase, building inventory and taking on additional debt to support growth initiatives, which positions it well for future expansion but requires monitoring of debt servicing capabilities.

Comparing 2026-02-04 vs 2025-02-13View on EDGAR →
FINANCIAL ANALYSIS

GEHC demonstrates robust financial strengthening across key metrics, with cash and equivalents jumping 56% to $4.5B and stockholders' equity growing 23% to $10.4B, indicating strong operational performance and improved financial flexibility. The company expanded its asset base by 11.5% while strategically increasing inventory by 15% and total debt by 12%, suggesting active investment in growth opportunities. The overall financial picture signals a company in expansion mode with significantly improved liquidity and capital position, though the increased debt load warrants attention to ensure sustainable growth.

FINANCIAL STATEMENT CHANGES
Cash & Equivalents
Balance Sheet
+56.3%
$2.9B→$4.5B

Cash position surged 56.3% — strong cash generation or capital raise providing significant financial cushion.

Current Assets
Balance Sheet
+26.3%
$9.9B→$12.5B

Current assets grew 26.3% — improving short-term liquidity or inventory/receivables build.

Stockholders Equity
Balance Sheet
+22.9%
$8.4B→$10.4B

Equity base grew 22.9% — retained earnings accumulation or equity issuance strengthening the balance sheet.

Dividends Paid
Cash Flow
+16.4%
$55.0M→$64.0M

Dividend payments increased 16.4% — management confidence in sustained cash generation.

Inventory
Balance Sheet
+15.2%
$1.9B→$2.2B

Inventory built 15.2% — monitor whether demand supports this build or if write-downs may follow.

Total Debt
Balance Sheet
+11.8%
$9.0B→$10.0B

Debt rose 11.8% — additional borrowing for investment or operations; monitor coverage ratios.

Total Assets
Balance Sheet
+11.5%
$33.1B→$36.9B

Asset base grew 11.5% — expansion through organic growth, acquisitions, or capital deployment.

LANGUAGE CHANGES
NEW — 2026-02-04
PRIOR — 2025-02-13
ADDED
There were 455,749,767 shares of common stock with a par value of $0.01 per share outstanding as of January 28, 2026.
Management s Discussion and Analysis of Financial Condition and Results of Operations 38 Trends and Factors Impacting Our Performance 38 Summary of Key Performance Measures 39 Results of Operations 40 Results of Operations Segments 42 Non-GAAP Financial Measures 43 Liquidity and Capital Resources 47 Recently Issued Accounting Pronouncements 48 Critical Accounting Estimates 48 Item 7A.
34 ) 53 Consolidated Statements of Income 56 Consolidated Statements of Comprehensive Income (Loss) 57 Consolidated Statements of Financial Position 58 Consolidated Statements of Changes in Equity 59 Consolidated Statements of Cash Flows 60 Notes to the Consolidated Financial Statements 61 Note 1.
Please also see Item 1A, Risk Factors of this Annual Report on Form 10-K filed with the United States ( U.S.
) Securities and Exchange Commission ( SEC ) and any updates or amendments we make in future filings.
( GE HealthCare, the Company, our, us, or we ) is a leading global healthcare solutions provider of advanced medical technology, pharmaceutical diagnostics, and AI, cloud and software solutions that help clinicians tackle the world s most complex diseases.
We have approximately 54,000 colleagues dedicated to our purpose to create a world where healthcare has no limits.
Serving patients and providers for nearly 130 years, GE HealthCare is delivering bold innovations designed for the next era of medicine to help clinicians deliver more personalized, precise patient care.
This is complemented by our broad service capabilities and dedication to quality and integrity with a strong operational culture, supported by our lean business system, Heartbeat.
We generate revenue from the sale of medical devices, consumable products, service capabilities, and AI-enabled cloud and software solutions.
REMOVED
There were 457,298,310 shares of common stock with a par value of $0.01 per share outstanding as of February 6, 2025.
Management s Discussion and Analysis of Financial Condition and Results of Operation s 38 Item 7A.
Please also see Item 1A, Risk Factors of this Annual Report on Form 10-K filed with the United States Securities and Exchange Commission ( SEC ) and any updates or amendments we make in future filings.
( GE HealthCare, the Company, our, or we ) is a trusted partner and leading global healthcare solutions provider, innovating medical technology, pharmaceutical diagnostics, and integrated, cloud-first AI-enabled solutions, services, and data analytics.
We have approximately 53,000 colleagues dedicated to our mission to create a world where healthcare has no limits.
We operate at the center of the healthcare ecosystem, enabling precision care by increasing health system capacity, enhancing productivity, digitizing healthcare delivery, and improving clinical outcomes while serving patients demand for greater efficiency, access, and personalized medicine.
Our products, services, and solutions are designed to enable clinicians to make more informed decisions quickly and efficiently, improving patient care from screening and diagnosis to therapy and monitoring.
We have more than 125 years of experience and one of the strongest reputations in the global healthcare industry, built from our demonstrated record of delivering industry-defining innovation.
This is complemented by our broad service capabilities and dedication to quality and integrity with a strong operational culture, deeply embedded in lean continuous improvement.
Precision care is expected to drive continued demand and the need for novel technologies and future innovation, as healthcare providers and researchers seek new solutions and tools for managing various disease states.
MORE FINANCIAL SIGNALS
CRMHIGHSalesforce significantly increased debt by 71% to $14.4B while simultaneously ac...
2026-03-02
UNHHIGHUNH's operating income plummeted 41% despite 12% revenue growth, indicating seve...
2026-03-02
PFEHIGHPfizer achieved a dramatic 87.3% reduction in total debt from $31.4B to $4.0B, r...
2026-02-26
GILDHIGHGILD dramatically increased R&D spending by 81.5% to $9.1B while introducing new...
2026-02-24
ANALYZE ANY FILING FREE

See what changed in your portfolio's filings

500+ US-listed companies analyzed. Language delta, financial analysis, instant signal scoring.

Try Tracenotes free →